Sichuan Kelun-Biotech Biopharmaceutical (6990 HK)

113

Analysis

Health Care • China

Sichuan Kelun-Biotech Biopharmaceutical is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biological and small molecule drugs, particularly Antibody-Drug Conjugates (ADCs). It addresses unmet medical needs in oncology, autoimmune disorders, and metabolic diseases, with key products including sacituzumab tirumotecan and trastuzumab botidotin. The company is headquartered in Chengdu, Sichuan, China, and was founded in 2016.

Refresh

Exchange Announcement • 17 Sep 2026 21:43

2026 Interim Report

Exchange Announcement • 08 Sep 2026 20:00

Voluntary Announcement Positive Phase 2 Interim Results And Initiation Of Phase 3 Study Of Skb378/Win378 In Asthma

Exchange Announcement • 17 Aug 2026 19:10

Interim Results Announcement For The Six Months Ended June 30, 2026

Exchange Announcement • 05 Aug 2026 16:30

Notice Of Board Meeting

Exchange Announcement • 04 Aug 2026 20:29

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

2026 Interim Report

Voluntary Announcement Positive Phase 2 Interim Results And Initiation Of Phase 3 Study Of Skb378/Win378 In Asthma

Interim Results Announcement For The Six Months Ended June 30, 2026

Notice Of Board Meeting

Discloseable Transaction Subscription For Wealth Management Product